FI3666797T3 - Antigeeniä sitovia proteiineja tyypin 9 proproteiinikonvertaasi-subtilisiini-keksiinille (pcsk9) - Google Patents

Antigeeniä sitovia proteiineja tyypin 9 proproteiinikonvertaasi-subtilisiini-keksiinille (pcsk9) Download PDF

Info

Publication number
FI3666797T3
FI3666797T3 FIEP19207796.4T FI19207796T FI3666797T3 FI 3666797 T3 FI3666797 T3 FI 3666797T3 FI 19207796 T FI19207796 T FI 19207796T FI 3666797 T3 FI3666797 T3 FI 3666797T3
Authority
FI
Finland
Prior art keywords
antigen
binding fragment
monoclonal antibody
antibody
use according
Prior art date
Application number
FIEP19207796.4T
Other languages
English (en)
Finnish (fi)
Inventor
Simon Mark Jackson
Nigel Pelham Walker
Derek Evan Piper
Bei Shan
Wenyan Shen
Joyce Chi Chan
Chadwick Terence King
Randal Robert Ketchem
Christopher Mehlin
Teresa Arazas Carabeo
Quiong Cao
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39951467&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI3666797(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of FI3666797T3 publication Critical patent/FI3666797T3/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
FIEP19207796.4T 2007-08-23 2008-08-22 Antigeeniä sitovia proteiineja tyypin 9 proproteiinikonvertaasi-subtilisiini-keksiinille (pcsk9) FI3666797T3 (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US95766807P 2007-08-23 2007-08-23
US896507P 2007-12-21 2007-12-21
US1063008P 2008-01-09 2008-01-09
US8613308P 2008-08-04 2008-08-04

Publications (1)

Publication Number Publication Date
FI3666797T3 true FI3666797T3 (fi) 2023-05-25

Family

ID=39951467

Family Applications (2)

Application Number Title Priority Date Filing Date
FIEP19207796.4T FI3666797T3 (fi) 2007-08-23 2008-08-22 Antigeeniä sitovia proteiineja tyypin 9 proproteiinikonvertaasi-subtilisiini-keksiinille (pcsk9)
FIEP08798550.3T FI2215124T4 (fi) 2007-08-23 2016-08-24 Antigeenia sitovat proteiinit proproteiinikonvertaasi-subtilisiini-keksiini tyypille 9 (PCSK9)

Family Applications After (1)

Application Number Title Priority Date Filing Date
FIEP08798550.3T FI2215124T4 (fi) 2007-08-23 2016-08-24 Antigeenia sitovat proteiinit proproteiinikonvertaasi-subtilisiini-keksiini tyypille 9 (PCSK9)

Country Status (42)

Country Link
US (27) US8030457B2 (enExample)
EP (3) EP3666797B1 (enExample)
JP (8) JP5441905B2 (enExample)
KR (10) KR20180035947A (enExample)
CN (8) CN104311665A (enExample)
AR (1) AR068011A1 (enExample)
AU (1) AU2008288791B2 (enExample)
BR (2) BRPI0816117B8 (enExample)
CA (1) CA2696252C (enExample)
CL (1) CL2008002495A1 (enExample)
CO (1) CO6230997A2 (enExample)
CR (1) CR11328A (enExample)
CY (3) CY1117940T1 (enExample)
DE (2) DE19207796T9 (enExample)
DK (2) DK3666797T5 (enExample)
EA (1) EA032106B1 (enExample)
ES (4) ES2573258T5 (enExample)
FI (2) FI3666797T3 (enExample)
FR (1) FR16C0025I2 (enExample)
HR (2) HRP20230503T3 (enExample)
HU (4) HUE028162T2 (enExample)
IL (5) IL273353B2 (enExample)
JO (1) JOP20080381B1 (enExample)
LT (3) LT3666797T (enExample)
LU (2) LU93096I2 (enExample)
MA (1) MA31978B1 (enExample)
MX (3) MX2010001921A (enExample)
MY (3) MY180102A (enExample)
NL (1) NL300818I2 (enExample)
NO (3) NO2016010I1 (enExample)
NZ (1) NZ584101A (enExample)
PE (8) PE20091006A1 (enExample)
PH (2) PH12013502285B1 (enExample)
PL (2) PL2215124T5 (enExample)
PT (1) PT3666797T (enExample)
RS (2) RS54756B2 (enExample)
SG (2) SG10201710183TA (enExample)
SI (2) SI2215124T2 (enExample)
TN (1) TN2010000063A1 (enExample)
TW (7) TWI441833B (enExample)
UA (1) UA127402C2 (enExample)
WO (1) WO2009026558A1 (enExample)

Families Citing this family (244)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2990420T (pt) 2000-05-26 2017-03-16 Immunex Corp Uso de anticorpos de recetor de interleucina-4 e composições dos mesmos
US7605251B2 (en) 2006-05-11 2009-10-20 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the PCSK9 gene
CA2667894A1 (en) 2006-11-07 2008-05-15 Merck & Co., Inc. Antagonists of pcsk9
JOP20080381B1 (ar) * 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
EP4248976B1 (en) 2007-08-23 2026-04-22 Amgen Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9)
CL2008002775A1 (es) 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
CA2713379A1 (en) * 2008-01-31 2009-11-05 Alnylam Pharmaceuticals, Inc. Optimized methods for delivery of dsrna targeting the pcsk9 gene
AR070316A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
AR070315A1 (es) * 2008-02-07 2010-03-31 Merck & Co Inc Anticuerpos 1b20 antagonistas de pcsk9
EP2641918A3 (en) 2008-08-04 2014-03-05 Amgen Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
TWI445716B (zh) * 2008-09-12 2014-07-21 Rinat Neuroscience Corp Ｐｃｓｋ９拮抗劑類
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
US20130064834A1 (en) 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
US8357371B2 (en) 2008-12-15 2013-01-22 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to PCSK9
NZ597504A (en) * 2009-06-15 2013-10-25 Alnylam Pharmaceuticals Inc Lipid formulated dsrna targeting the pcsk9 gene
US9051567B2 (en) 2009-06-15 2015-06-09 Tekmira Pharmaceuticals Corporation Methods for increasing efficacy of lipid formulated siRNA
WO2011028938A1 (en) * 2009-09-02 2011-03-10 Alnylam Pharmaceuticals, Inc. Methods for lowering serum cholestrol in a subject using inhibition of pcsk9
KR101660578B1 (ko) * 2009-09-03 2016-09-27 화이자 백신스 엘엘씨 Ｐｃｓｋ９ 백신
US20120219558A1 (en) * 2009-09-25 2012-08-30 Yan Ni Antagonists of pcsk9
CA2777698A1 (en) 2009-10-30 2011-05-05 Merck Sharp & Dohme Corp. Ax1 and ax189 pcsk9 antagonists and variants
AU2010313324A1 (en) * 2009-10-30 2012-04-12 Merck Sharp & Dohme Corp. AX213 and AX132 PCSK9 antagonists and variants
WO2011053743A1 (en) * 2009-10-30 2011-05-05 Merck Sharp & Dohme Corp. Pcsk9 immunoassay
AR079336A1 (es) * 2009-12-11 2012-01-18 Irm Llc Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)
WO2011087934A2 (en) * 2010-01-12 2011-07-21 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Kexin-derived vaccines to prevent or treat fungal infections
US9181538B1 (en) 2010-01-12 2015-11-10 Karen A. Norris Kexin-based vaccines to prevent or treat fungal infections
NZ602220A (en) * 2010-03-11 2014-10-31 Rinat Neuroscience Corp Antibodies with ph dependent antigen binding
JO3756B1 (ar) 2010-11-23 2021-01-31 Regeneron Pharma اجسام مضادة بشرية لمستقبلات الجلوكاجون
CA2825778A1 (en) * 2011-01-28 2012-08-02 Sanofi Pharmaceutical compositions comprising human antibodies to pcsk9
EP2650016A1 (en) * 2011-01-28 2013-10-16 Sanofi Human antibodies to PSCK9 for use in methods of treatment based on particular dosage regimens (11565)
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US12279989B2 (en) 2011-02-04 2025-04-22 Seed Health, Inc. Method and system for increasing beneficial bacteria and decreasing pathogenic bacteria in the oral cavity
US12533312B2 (en) 2011-02-04 2026-01-27 Seed Health, Inc. Method and system for preventing sore throat in humans
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US9730967B2 (en) 2011-02-04 2017-08-15 Katherine Rose Kovarik Method and system for treating cancer cachexia
US10314865B2 (en) 2011-02-04 2019-06-11 Katherine Rose Kovarik Method and system for treating cancer and other age-related diseases by extending the healthspan of a human
US11998479B2 (en) 2011-02-04 2024-06-04 Seed Health, Inc. Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure
US12257272B2 (en) 2015-12-24 2025-03-25 Seed Health, Inc. Method and system for reducing the likelihood of developing depression in an individual
MX2013009258A (es) * 2011-02-11 2013-10-17 Novartis Ag Antagonistas de pcsk9.
SG10201609665PA (en) 2011-02-25 2017-01-27 Chugai Pharmaceutical Co Ltd FcɣRIIb-SPECIFIC Fc ANTIBODY
JP6081714B2 (ja) * 2011-04-28 2017-02-15 株式会社ビー・エム・エル 高コレステロール血症と動脈硬化の検出方法
SG10201900183VA (en) 2011-04-28 2019-05-30 Univ Leland Stanford Junior Identification of polynucleotides associated with a sample
AR088782A1 (es) * 2011-04-29 2014-07-10 Sanofi Sa Sistemas de ensayo y metodos para identificar y caracterizar farmacos hipolipemiantes
JOP20200043A1 (ar) * 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
US20140004122A1 (en) * 2011-05-10 2014-01-02 Amgen Inc. Methods for treating or preventing cholesterol related disorders
WO2012170607A2 (en) * 2011-06-10 2012-12-13 Novartis Ag Use of pcsk9 antagonists
WO2012168491A1 (en) * 2011-06-10 2012-12-13 Novartis Ag Pharmaceutical formulations of pcsk9 antagonists
WO2013002362A1 (ja) 2011-06-30 2013-01-03 中外製薬株式会社 ヘテロ二量化ポリペプチド
WO2013008185A1 (en) * 2011-07-14 2013-01-17 Pfizer Inc. Treatment with anti-pcsk9 antibodies
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
AR087715A1 (es) * 2011-09-16 2014-04-09 Lilly Co Eli Anticuerpos anti pcsk9 y usos de los mismos
ES2773111T3 (es) 2011-09-16 2020-07-09 Regeneron Pharma Inhibidor de la proproteína convertasa subtilisina/kexina 9 (PCSK9) para su uso en la reducción de los niveles de lipoproteína (a)
JP6322411B2 (ja) 2011-09-30 2018-05-09 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
EP3045187B1 (en) 2011-10-14 2019-04-10 Amgen Inc. Injector and method of assembly
WO2013058762A1 (en) * 2011-10-21 2013-04-25 Tanvex Biologics Corp. Separation of acetylated proteins from unacetylated proteins
KR20210074395A (ko) 2011-11-30 2021-06-21 추가이 세이야쿠 가부시키가이샤 면역 복합체를 형성하는 세포내로의 운반체（캐리어）를 포함하는 의약
CA2865158C (en) 2012-02-24 2022-11-01 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule for promoting disappearance of antigen via fc.gamma.riib
AU2013247645B2 (en) * 2012-04-09 2019-02-14 Daiichi Sankyo Company, Limited Anti-FGFR2 antibody
US9321681B2 (en) * 2012-04-27 2016-04-26 United States Gypsum Company Dimensionally stable geopolymer compositions and method
EA039663B1 (ru) * 2012-05-03 2022-02-24 Амген Инк. Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
US9255154B2 (en) * 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
WO2013170367A1 (en) * 2012-05-17 2013-11-21 The University Of British Columbia Methods and uses for proprotein convert ase subtilisin kexin 9 (pcsk9) inhibitors
EP2667197B1 (en) 2012-05-25 2015-09-16 Zora Biosciences OY Sensitive efficacy and specificity biomarkers for proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition
JP2013253842A (ja) 2012-06-06 2013-12-19 Univ Of Tokyo ｐＨ依存的に標的分子に結合するペプチドのスクリーニング方法
AR091462A1 (es) 2012-06-15 2015-02-04 Genentech Inc Anticuerpos anti-pcsk9, formulaciones, dosificacion y metodos de uso
NZ704771A (en) * 2012-08-13 2018-02-23 Regeneron Pharma Anti-pcsk9 antibodies with ph-dependent binding characteristics
TWI855488B (zh) 2012-08-24 2024-09-11 日商中外製藥股份有限公司 FcγRIIb特異性Fc區域變異體
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
BR112015013105B1 (pt) 2012-12-05 2022-02-08 Alnylam Pharmaceuticals, Inc Agente de rnai de fita dupla capaz de inibir a expressão de pcsk9, seus usos, composição farmacêutica e método de inibição da expressão de pcsk9 em uma célula in vitro
CN105102618B (zh) 2012-12-27 2018-04-17 中外制药株式会社 异源二聚化多肽
US10287317B2 (en) * 2013-02-15 2019-05-14 Srx Cardio, Llc Proprotein convertase subtilisin kexin type 9 (PCSK9) allosteric binding ligands to modulate serum low density lipoprotein (LDL) levels
WO2014149699A1 (en) 2013-03-15 2014-09-25 Eli Lilly And Company Bifunctional protein
AU2014235430A1 (en) * 2013-03-15 2015-09-24 Amgen Inc. Human antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9 (PCSK9)
WO2014144817A2 (en) 2013-03-15 2014-09-18 Amgen Inc. Inhibitory polypeptides specific to wnt inhibitors
ES2853748T3 (es) 2013-03-22 2021-09-17 Amgen Inc Inyector y método de montaje
SG11201508170TA (en) 2013-04-02 2015-11-27 Chugai Pharmaceutical Co Ltd Fc REGION VARIANT
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
JP6417118B2 (ja) * 2013-05-31 2018-10-31 株式会社ビー・エム・エル Ｐｃｓｋ９測定用標準物質
TW201534324A (zh) 2013-06-07 2015-09-16 Sanofi Sa 藉由投與ｐｃｓｋ９抑制劑抑制動脈粥狀硬化的方法
EP2862877A1 (en) 2013-10-18 2015-04-22 Sanofi Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9
US20150004174A1 (en) * 2013-06-28 2015-01-01 Amgen Inc. Methods for treating homozygous familial hypercholesterolemia
JP6267792B2 (ja) * 2013-06-28 2018-01-24 アムジエン・インコーポレーテツド ホモ接合性家族性高コレステロール血症の治療方法
EP3712166A1 (en) 2013-09-05 2020-09-23 Amgen Inc. Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
EP3060275B1 (en) 2013-10-24 2019-07-03 Amgen Inc. Injector and method of assembly
US10428157B2 (en) 2013-11-12 2019-10-01 Sanofi Biotechnology Dosing regimens for use with PCSK9 inhibitors
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
DE202014010499U1 (de) 2013-12-17 2015-10-20 Kymab Limited Targeting von humaner PCSK9 zur Cholesterinbehandlung
CN106062004A (zh) * 2013-12-17 2016-10-26 科马布有限公司 人靶标
US8986694B1 (en) 2014-07-15 2015-03-24 Kymab Limited Targeting human nav1.7 variants for treatment of pain
US9067998B1 (en) 2014-07-15 2015-06-30 Kymab Limited Targeting PD-1 variants for treatment of cancer
US9051378B1 (en) 2014-07-15 2015-06-09 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9023359B1 (en) 2014-07-15 2015-05-05 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
GB2521356B (en) * 2013-12-17 2018-10-10 Kymab Ltd Antibodies for use in treating conditions related to specific PCKS9 variants and associated diagnostic methods
WO2015092394A1 (en) * 2013-12-17 2015-06-25 Kymab Limited Antibodies for use in treating conditions related to specific pcsk9 variants in specific patients populations
US9034332B1 (en) 2014-07-15 2015-05-19 Kymab Limited Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8945560B1 (en) 2014-07-15 2015-02-03 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
FR3014695A1 (enExample) * 2013-12-17 2015-06-19 Kymab Ltd
US8992927B1 (en) 2014-07-15 2015-03-31 Kymab Limited Targeting human NAV1.7 variants for treatment of pain
US9045548B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment
EP2975058A1 (en) * 2014-07-15 2016-01-20 Kymab Limited Antibodies for use in treating conditions related to specific PCSK9 variants in specific patient populations
EP2886558A1 (en) * 2013-12-17 2015-06-24 Kymab Limited Antibodies for use in treating conditions related to specific PCSK9 variants in specific patient populations
US9045545B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
US8883157B1 (en) 2013-12-17 2014-11-11 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US12246043B2 (en) 2013-12-20 2025-03-11 Seed Health, Inc. Topical application to treat acne vulgaris
US11969445B2 (en) 2013-12-20 2024-04-30 Seed Health, Inc. Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
US12005085B2 (en) 2013-12-20 2024-06-11 Seed Health, Inc. Probiotic method and composition for maintaining a healthy vaginal microbiome
US12329783B2 (en) 2013-12-20 2025-06-17 Seed Health, Inc. Method and system to improve the health of a person's skin microbiome
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
US11998574B2 (en) 2013-12-20 2024-06-04 Seed Health, Inc. Method and system for modulating an individual's skin microbiome
US11980643B2 (en) 2013-12-20 2024-05-14 Seed Health, Inc. Method and system to modify an individual's gut-brain axis to provide neurocognitive protection
JP6608368B2 (ja) 2013-12-30 2019-11-20 アトレカ インコーポレイテッド 核酸バーコードを用いた単一細胞と関連づけられた核酸の分析方法
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
WO2015175861A1 (en) 2014-05-16 2015-11-19 Amgen Inc. Assay for detecting th1 and th2 cell populations
WO2015200438A1 (en) * 2014-06-24 2015-12-30 Eleven Biotherapeutics, Inc. High affinity antibodies against pcsk9
US20170198059A1 (en) 2014-07-14 2017-07-13 Amgen Inc. Crystalline antibody formulations
CA2954773C (en) * 2014-07-14 2023-10-03 Amgen Inc. Crystalline antibody formulations
DE202015009006U1 (de) 2014-07-15 2016-08-19 Kymab Limited Targeting von humaner PCSK9 zur Cholesterinbehandlung
EP4328245A3 (en) 2014-07-15 2024-06-05 Kymab Ltd. Antibodies for use in treating conditions related to specific pcsk9 variants in specific patients populations
EP3332790A1 (en) 2014-07-15 2018-06-13 Kymab Limited Antibodies for use in treating conditions related to specific pcsk9 variants in specific patients populations
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
US9150660B1 (en) 2014-07-15 2015-10-06 Kymab Limited Precision Medicine by targeting human NAV1.8 variants for treatment of pain
KR20230074283A (ko) 2014-07-16 2023-05-26 사노피 바이오테크놀로지 이형접합성 가족성 고콜레스테롤혈증(heFH) 환자의 치료방법
PT3177644T (pt) 2014-08-05 2021-01-13 MabQuest SA Reagentes imunológicos que se ligam a pd-1
US9982052B2 (en) 2014-08-05 2018-05-29 MabQuest, SA Immunological reagents
JP2017523980A (ja) 2014-08-06 2017-08-24 ライナット ニューロサイエンス コーポレイション Ｌｄｌ−コレステロールを低下させるための方法
WO2016020799A1 (en) 2014-08-06 2016-02-11 Rinat Neuroscience Corp. Methods for reducing ldl-cholesterol
WO2016023916A1 (en) 2014-08-12 2016-02-18 Kymab Limited Treatment of disease using ligand binding to targets of interest
EP3194441A1 (en) 2014-09-16 2017-07-26 Regeneron Pharmaceuticals, Inc. Anti-glucagon antibodies and uses thereof
EP3197492A1 (en) 2014-09-23 2017-08-02 Pfizer Inc Treatment with anti-pcsk9 antibodies
ES2964713T3 (es) 2014-10-23 2024-04-09 Amgen Inc Reducción de la viscosidad de formulaciones farmacéuticas
WO2016071701A1 (en) 2014-11-07 2016-05-12 Kymab Limited Treatment of disease using ligand binding to targets of interest
MX2017005774A (es) 2014-12-19 2017-07-28 Chugai Pharmaceutical Co Ltd Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso.
CN114773469B (zh) 2015-02-05 2025-12-19 中外制药株式会社 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用
CN105461809B (zh) * 2015-02-11 2018-10-12 康融东方（广东）医药有限公司 Pcsk9抗体、其药物组合物及其用途
US9139653B1 (en) 2015-04-30 2015-09-22 Kymab Limited Anti-human OX40L antibodies and methods of treatment
TW201639891A (zh) 2015-03-10 2016-11-16 索倫多醫療公司 結合ｐｓｍａ之抗體治療劑
EP3271405A1 (en) 2015-03-20 2018-01-24 Aarhus Universitet Inhibitors of pcsk9 for treatment of lipoprotein metabolism disorders
AU2016248997B2 (en) * 2015-04-15 2019-03-07 ConcieValve LLC Devices and methods for inhibiting stenosis, obstruction, or calcification of a native heart valve, stented heart valve or bioprosthesis
CN105037554B (zh) * 2015-06-12 2019-04-12 成都贝爱特生物科技有限公司 抗人pcsk9抗体的制备及其用途
CN114350752B (zh) 2015-07-17 2025-02-25 布鲁克空间生物学公司 在横切面组织的用户定义区域中的基因表达的同时定量
EA201890519A1 (ru) 2015-08-18 2018-07-31 Ридженерон Фармасьютикалз, Инк. Ингибирующие антитела против pcsk9 для лечения пациентов с гиперлипидемией, подвергающихся аферезу липопротеинов
AU2016332900C1 (en) 2015-09-29 2024-07-04 Amgen Inc. ASGR inhibitors
WO2017055966A1 (en) 2015-10-01 2017-04-06 Pfizer Inc. Low viscosity antibody compositions
CN106589127A (zh) * 2015-10-16 2017-04-26 钜川生物医药 一种pcsk9抗体及其制备方法和应用
CN105348390B (zh) * 2015-10-26 2018-08-28 北京智仁美博生物科技有限公司 抗人pcsk9单克隆抗体
WO2017106326A1 (en) * 2015-12-14 2017-06-22 The Trustees Of The University Of Pennsylvania Aav-anti pcsk9 antibody constructs and uses thereof
EP3394098A4 (en) 2015-12-25 2019-11-13 Chugai Seiyaku Kabushiki Kaisha ANTI-MYOSTATIN ANTIBODIES AND METHOD OF USE
CN107406511B (zh) * 2015-12-31 2021-01-19 江苏恒瑞医药股份有限公司 Pcsk9抗体、其抗原结合片段及其医药用途
CN107531795B (zh) 2016-01-05 2021-01-19 江苏恒瑞医药股份有限公司 Pcsk9抗体、其抗原结合片段及其医药用途
US11214617B2 (en) 2016-01-22 2022-01-04 MabQuest SA Immunological reagents
PL3964529T3 (pl) 2016-01-22 2025-10-27 MabQuest SA Nieblokujące przeciwciała specyficzne względem pd1
GB201604124D0 (en) 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation
US11066464B2 (en) 2016-03-21 2021-07-20 Kymab Limited Anti-malarial antibodies that bind circumsporozoite protein
WO2017163049A1 (en) 2016-03-21 2017-09-28 Kymab Limited Anti-malarial antibodies that bind circumsporozoite protein
CN107266575B (zh) * 2016-04-07 2021-12-24 天士力生物医药股份有限公司 前蛋白转化酶枯草溶菌素kexin 9型的结合蛋白及其应用
WO2017200989A1 (en) 2016-05-16 2017-11-23 Amgen Inc. Data encryption in medical devices with limited computational capability
CN107474140B (zh) * 2016-06-08 2022-06-03 常州博嘉生物医药科技有限公司 Pcsk9特异性的结合蛋白mv072及其应用
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
WO2018029474A2 (en) 2016-08-09 2018-02-15 Kymab Limited Anti-icos antibodies
CN116271014A (zh) 2016-08-05 2023-06-23 中外制药株式会社 用于预防或治疗il-8相关疾病的组合物
KR20190049866A (ko) * 2016-09-20 2019-05-09 우시 바이올로직스 아일랜드 리미티드 신규한 항-ｐｃｓｋ９ 항체
TWI782920B (zh) * 2016-09-20 2022-11-11 中國大陸商上海藥明生物技術有限公司 新型抗-pcsk9抗體
JP7275027B2 (ja) 2016-10-06 2023-05-17 アムジェン インコーポレイテッド 粘度低下タンパク質医薬製剤
WO2018075792A1 (en) 2016-10-20 2018-04-26 Regeneron Pharmaceuticals, Inc. Methods of lowering blood glucose levels
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
CN106822881A (zh) * 2016-12-09 2017-06-13 四川大学 一种针对pcsk9的抗高血脂蛋白疫苗
CN108239150A (zh) 2016-12-24 2018-07-03 信达生物制药(苏州)有限公司 抗pcsk9抗体及其用途
WO2018136398A1 (en) 2017-01-17 2018-07-26 Amgen Inc. Injection devices and related methods of use and assembly
CN110944651A (zh) 2017-02-08 2020-03-31 蜻蜓疗法股份有限公司 用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途
AU2018220538B2 (en) 2017-02-17 2023-12-14 Amgen Inc. Drug delivery device with sterile fluid flowpath and related method of assembly
EP4273258A3 (en) 2017-02-20 2024-01-17 Dragonfly Therapeutics, Inc. Proteins binding her2, nkg2d and cd16
JP7377596B2 (ja) 2017-02-22 2023-11-10 アムジエン・インコーポレーテツド 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法
US10093731B2 (en) 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use
AU2018235928B2 (en) 2017-03-14 2023-09-21 Amgen Inc. Control of total afucosylated glycoforms of antibodies produced in cell culture
US12023041B2 (en) 2017-03-21 2024-07-02 Teleflex Medical Incorporated Clip applier
CN110740695B (zh) 2017-03-21 2024-10-25 泰利福医疗公司 手术夹和施夹器
JP2020529581A (ja) * 2017-05-31 2020-10-08 ノースカロライナ・セントラルユニバーシティＮｏｒｔｈ Ｃａｒｏｌｉｎａ Ｃｅｎｔｒａｌ Ｕｎｉｖｅｒｓｉｔｙ アクティブｐｃｓｋ９アッセイの最適化
CN107029243A (zh) * 2017-06-08 2017-08-11 厦门大学 一种多肽桥连的双酰腙连接键应用于醛衍生药物的递送
GB201709970D0 (en) 2017-06-22 2017-08-09 Kymab Ltd Bispecific antigen-binding molecules
JP7649105B2 (ja) 2017-07-21 2025-03-19 アムジエン・インコーポレーテツド 薬物容器のためのガス透過性シーリング部材及び組立方法
WO2019022951A1 (en) 2017-07-25 2019-01-31 Amgen Inc. DRUG DELIVERY DEVICE WITH GEAR MODULE AND ASSEMBLY METHOD THEREOF
EP3658206A1 (en) 2017-07-25 2020-06-03 Amgen Inc. Drug delivery device with container access system and related method of assembly
EP3668567B1 (en) 2017-08-18 2026-02-18 Amgen Inc. Wearable injector with sterile adhesive patch
JP6913566B2 (ja) * 2017-08-23 2021-08-04 協同油脂株式会社 グリース組成物
EP3691717B1 (en) 2017-10-04 2023-02-08 Amgen Inc. Flow adapter for drug delivery device
ES3069718T3 (en) 2017-11-03 2026-06-10 Amgen Inc System and approaches for sterilizing a drug delivery device
EP4640703A3 (en) 2017-11-14 2026-04-08 Chugai Seiyaku Kabushiki Kaisha Anti-c1s antibodies and methods of use
AU2018368340B2 (en) 2017-11-16 2024-03-07 Amgen Inc. Door latch mechanism for drug delivery device
GB201721338D0 (en) 2017-12-19 2018-01-31 Kymab Ltd Anti-icos Antibodies
JP6639463B2 (ja) * 2017-12-21 2020-02-05 アムジエン・インコーポレーテツド ホモ接合性家族性高コレステロール血症の治療方法
WO2019152599A1 (en) * 2018-01-31 2019-08-08 The Wistar Institute Of Anatomy And Biology Nucleic acid monoclonal antibodies targeting pcsk9 and methods of use
CA3090244A1 (en) 2018-02-08 2019-08-15 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the nkg2d receptor
MX2020008333A (es) 2018-02-08 2020-09-21 Dragonfly Therapeutics Inc Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales.
EA202091976A1 (ru) * 2018-02-20 2021-07-06 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на cd33, и их применение
CN112119093A (zh) 2018-02-20 2020-12-22 蜻蜓治疗公司 结合cd33、nkg2d和cd16的多特异性结合蛋白和使用方法
US12325737B2 (en) 2018-03-26 2025-06-10 Amgen Inc. Total afucosylated glycoforms of antibodies produced in cell culture
EP3774879B1 (en) 2018-03-30 2026-01-28 Amgen Inc. C-terminal antibody variants
CA3102032A1 (en) 2018-06-05 2019-12-12 Anji Pharma (Us) Llc Compositions and methods for treating pancreatitis
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
CA3108427A1 (en) 2018-08-08 2020-02-13 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use
CN113164570B (zh) 2018-08-08 2024-05-14 蜻蜓疗法股份有限公司 结合nkg2d、cd16和肿瘤相关抗原的蛋白质
MX2021001431A (es) 2018-08-10 2021-05-12 Chugai Pharmaceutical Co Ltd Molecula de union al antigeno anti grupo de diferenciacion 137 (cd137) y su uso.
EP3856047A4 (en) 2018-09-26 2022-06-22 Teleflex Medical Incorporated STAPLER APPLICATOR WITH STABILIZATION ELEMENT
JP7627216B2 (ja) * 2018-11-16 2025-02-05 メモリアル スローン ケタリング キャンサー センター ムチン－１６に対する抗体およびそれを使用する方法
GB201820687D0 (en) 2018-12-19 2019-01-30 Kymab Ltd Antagonists
CN109776680B (zh) * 2019-01-25 2020-05-12 浙江蓝盾药业有限公司 抗人pcsk9单克隆抗体及其用途
CA3137649A1 (en) 2019-05-15 2020-11-19 Chugai Seiyaku Kabushiki Kaisha An antigen-binding molecule, a pharmaceutical composition, and a method
EP3969620B1 (en) 2019-05-17 2025-06-25 Regeneron Pharmaceuticals, Inc. Genome-based methods for reducing cardiovascular risk
JP7671275B2 (ja) 2019-08-29 2025-05-01 エランコ・ユーエス・インコーポレイテッド 動物用の抗ｉｌ３１抗体
US12570725B2 (en) 2019-09-13 2026-03-10 Duke University ZIKA antibodies and their use
WO2021058597A1 (en) 2019-09-24 2021-04-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of determining whether a subject is at risk of developing arterial plaques
GB201913846D0 (en) 2019-09-25 2019-11-06 King S College London Biomarker
KR20220069982A (ko) 2019-09-26 2022-05-27 암젠 인크 항체 조성물의 생산 방법
EP4045515A4 (en) 2019-10-18 2023-10-18 The Regents Of The University Of Michigan BIOMATERIAL SENSOR SYSTEMS
JP2023501745A (ja) * 2019-11-18 2023-01-18 エーディー ファーマシューティカルズ カンパニー，リミティド 抗ｐｃｓｋ９抗体及びその使用
EP4065607A1 (en) 2019-11-29 2022-10-05 Kymab Limited Treatment for physiological iron overload
CA3164996A1 (en) * 2019-12-20 2021-06-14 Novarock Biotherapeutics, Ltd. Anti-interleukin-23 p19 antibodies and methods of use thereof
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
AU2021268340A1 (en) 2020-05-06 2022-12-08 Dragonfly Therapeutics, Inc. Proteins binding NKG2D, CD16 and CLEC12A
WO2021247892A1 (en) 2020-06-04 2021-12-09 Amgen Inc. Assessment of cleaning procedures of a biotherapeutic manufacturing process
US20240043501A1 (en) 2020-10-15 2024-02-08 Amgen Inc. Relative unpaired glycans in antibody production methods
EP4301774A4 (en) 2021-03-03 2025-08-13 Dragonfly Therapeutics Inc METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN
WO2022207846A1 (en) 2021-03-31 2022-10-06 Cambridge Enterprise Limited Therapeutic inhibitors of gdf15 signalling
WO2022207785A1 (en) 2021-03-31 2022-10-06 Kymab Limited Antibodies to gfral
CA3219336A1 (en) 2021-05-18 2022-11-24 Kymab Limited Uses of anti-icos antibodies
GB202107994D0 (en) 2021-06-04 2021-07-21 Kymab Ltd Treatment of cancer
AU2022289365A1 (en) 2021-06-07 2023-12-14 Amgen Inc. Using fucosidase to control afucosylation level of glycosylated proteins
CN113480650B (zh) * 2021-06-30 2022-01-28 徐州医科大学 一种全人源靶向cd276的car-t细胞的制备方法及应用
MX2024001877A (es) 2021-08-10 2024-02-28 Kymab Ltd Tratamiento de dermatitis atopica.
JP2024537100A (ja) 2021-10-05 2024-10-10 アムジエン・インコーポレーテツド Ｆｃガンマ受容体ＩＩ結合、及びグリカン含量
WO2023076419A2 (en) * 2021-10-27 2023-05-04 Twist Bioscience Corporation Sars-cov-2 antibodies and methods of use
CN116948030B (zh) 2022-04-25 2024-11-19 武汉大学 抗asgr1单克隆抗体及其应用
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
EP4525991A1 (en) 2022-05-18 2025-03-26 Kymab Limited Uses of anti-icos antibodies
JP2026516670A (ja) 2023-04-20 2026-05-26 アムジエン・インコーポレーテツド 相対的な不対グリカン含有量を決定する方法
WO2025036347A1 (zh) * 2023-08-14 2025-02-20 信立泰(成都)生物技术有限公司 Pcsk9抑制剂用于治疗或预防胆固醇相关疾病的方法
AU2024325342A1 (en) 2023-08-14 2026-02-26 Amgen Inc. Methods for reducing yellow color
WO2025101820A1 (en) 2023-11-08 2025-05-15 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
WO2026090253A1 (en) 2024-10-23 2026-04-30 Amgen Inc. Methods of determining glycan pairing content

Family Cites Families (211)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US896507A (en) 1908-04-06 1908-08-18 Theodore J Asch Sweat-band.
US1063008A (en) 1913-03-15 1913-05-27 William E Budd Vehicle-tire.
US3180193A (en) 1963-02-25 1965-04-27 Benedict David Machines for cutting lengths of strip material
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS5612114B2 (enExample) 1974-06-07 1981-03-18
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
AU548996B2 (en) 1980-02-04 1986-01-09 Merck & Co., Inc. Tetrahydro-2h-pyran-2-one derivatives
US4444784A (en) * 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
FR2664073A1 (fr) 1990-06-29 1992-01-03 Thomson Csf Moyens de marquage d'objets, procede de realisation et dispositif de lecture.
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
CA2090473A1 (en) 1990-08-29 1992-03-01 Robert M. Kay Homologous recombinatin in mammalian cells
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1992022670A1 (en) 1991-06-12 1992-12-23 Genpharm International, Inc. Early detection of transgenic embryos
AU2235992A (en) 1991-06-14 1993-01-12 Genpharm International, Inc. Transgenic immunodeficient non-human animals
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
WO1993011794A1 (en) 1991-12-13 1993-06-24 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
JPH07503132A (ja) 1991-12-17 1995-04-06 ジェンファーム　インターナショナル，インコーポレイティド 異種抗体を産生することができるトランスジェニック非ヒト動物
WO1994000569A1 (en) 1992-06-18 1994-01-06 Genpharm International, Inc. Methods for producing transgenic non-human animals harboring a yeast artificial chromosome
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
US6066718A (en) 1992-09-25 2000-05-23 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
US5981175A (en) 1993-01-07 1999-11-09 Genpharm Internation, Inc. Methods for producing recombinant mammalian cells harboring a yeast artificial chromosome
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625825A (en) 1993-10-21 1997-04-29 Lsi Logic Corporation Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
US5643763A (en) 1994-11-04 1997-07-01 Genpharm International, Inc. Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1997000271A1 (en) 1995-06-14 1997-01-03 The Regents Of The University Of California Novel high affinity human antibodies to tumor antigens
US6127977A (en) 1996-11-08 2000-10-03 Cohen; Nathan Microstrip patch antenna with fractal structure
EP0773288A3 (en) 1995-08-29 1997-07-09 Kirin Brewery Chimera animal and its method of manufacture
GB9610992D0 (en) 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
AU4228997A (en) 1996-07-09 1998-02-02 Merck & Co., Inc. Method for treating homozygous familial hypercholesterolemia
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
US6133426A (en) 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
US7968689B2 (en) 1997-03-07 2011-06-28 Human Genome Sciences, Inc. Antibodies to HSDEK49 polypeptides
US20050197285A1 (en) 1997-03-07 2005-09-08 Rosen Craig A. Human secreted proteins
US20080103090A1 (en) 1997-03-07 2008-05-01 Human Genome Sciences, Inc. Human Secreted Proteins
US20070055056A1 (en) 1997-03-07 2007-03-08 Rosen Craig A 251 human secreted proteins
US7368531B2 (en) 1997-03-07 2008-05-06 Human Genome Sciences, Inc. Human secreted proteins
US20070015696A1 (en) 1997-03-07 2007-01-18 Rosen Craig A 621 human secreted proteins
US20060223090A1 (en) 1997-03-07 2006-10-05 Rosen Craig A Polynucleotides encoding human secreted proteins
US7411051B2 (en) 1997-03-07 2008-08-12 Human Genome Sciences, Inc. Antibodies to HDPPA04 polypeptide
US20070224663A1 (en) 1997-03-07 2007-09-27 Human Genome Sciences, Inc. Human Secreted Proteins
US20060246483A1 (en) 1997-03-07 2006-11-02 Rosen Craig A 337 human secreted proteins
US20060223088A1 (en) 1997-03-07 2006-10-05 Rosen Craig A Human secreted proteins
US20070059302A1 (en) 1997-04-07 2007-03-15 Genentech, Inc. Anti-vegf antibodies
US6252050B1 (en) 1998-06-12 2001-06-26 Genentech, Inc. Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method
FR2784749B1 (fr) 1998-10-14 2000-12-29 Instruments Sa Appareil de caracterisation optique de materiau en couche mince
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
GB2343233A (en) 1998-10-28 2000-05-03 Whitnash Plc Torsional vibration damper.
NL1011069C2 (nl) 1999-01-19 2000-07-20 Well Engineering Partners B V Werkwijze en installatie voor het inbrengen van een buis in een boorgat in de aardbodem.
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
EP1514933A1 (en) 1999-07-08 2005-03-16 Research Association for Biotechnology Secretory protein or membrane protein
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
US20030119038A1 (en) 1999-09-09 2003-06-26 Bingham Brendan William NARC1, novel subtilase-like homologs
US7029895B2 (en) 1999-09-27 2006-04-18 Millennium Pharmaceuticals, Inc. 27411, a novel human PGP synthase
US20100291099A1 (en) 1999-09-27 2010-11-18 Millennium Pharmaceuticals, Inc. Novel 27411, 23413, 22438, 23553, 25278, 26212, narc sc1, narc 10a, narc 1, narc 12, narc 13, narc17, narc 25, narc 3, narc 4, narc 7, narc 8, narc 11, narc 14a, narc 15, narc 16, narc 19, narc 20, narc 26, narc 27, narc 28, narc 30, narc 5, narc 6, narc 9, narc 10c, narc 8b, narc 9, narc2a, narc 16b, narc 1c, narc 1a, narc 25, 86604 and 32222 molecules and uses therefor
US20020081679A1 (en) 1999-10-22 2002-06-27 Millennium Pharmaceuticals, Inc. NARC8 programmed cell-death-associated molecules and uses thereof
US20110230392A1 (en) 1999-10-22 2011-09-22 Millennium Pharmaceuticals, Inc. Novel narc sc1, narc 10a, narc 1, narc 12, narc 13, narc17, narc 25, narc 3, narc 4, narc 7, narc 8, narc 11, narc 14a, narc 15, narc 16, narc 19, narc 20, narc 26, narc 27, narc 28, narc 30, narc 5, narc 6, narc 9, narc 10c, narc 8b, narc 9, narc2a, narc 16b, narc 1c, narc 1a, and narc 25 molecules and uses therefor
AU1099601A (en) 1999-10-22 2001-05-08 Millennium Pharmaceuticals, Inc. Nucleic acid molecules derived from rat brain and programmed cell death models
AU2001241461A1 (en) 2000-02-07 2001-08-14 Millennium Pharmaceuticals, Inc. Narc-1, novel subtilase-like homologs
JP3753917B2 (ja) 2000-03-17 2006-03-08 茨木精機株式会社 包装体の整列搬出方法及びその装置
EP1278778A2 (en) 2000-05-03 2003-01-29 Amgen Inc., Modified peptides, comprising an fc domain, as therapeutic agents
CA2411971A1 (en) 2000-06-16 2001-12-27 Incyte Genomics, Inc. Proteases
AU2001280471A1 (en) 2000-08-11 2002-02-25 Eli Lilly And Company Novel secreted proteins and their uses
DE60139944D1 (de) 2000-10-12 2009-10-29 Genentech Inc Niederviskose konzentrierte proteinformulierungen
JP2005500005A (ja) 2000-12-08 2005-01-06 インサイト・ゲノミックス・インコーポレイテッド タンパク質修飾分子とメンテナンス分子
EP1423134A2 (en) 2001-03-21 2004-06-02 Human Genome Sciences Human secreted proteins
US20070173473A1 (en) 2001-05-18 2007-07-26 Sirna Therapeutics, Inc. RNA interference mediated inhibition of proprotein convertase subtilisin Kexin 9 (PCSK9) gene expression using short interfering nucleic acid (siNA)
US20040023243A1 (en) 2001-06-13 2004-02-05 Yue Henry Proteases
IL159177A0 (en) 2001-06-20 2004-06-01 Prochon Biotech Ltd Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
US20040038242A1 (en) 2001-07-30 2004-02-26 Edmonds Brian Taylor Novel secreted proteins and their uses
AU2003213022A1 (en) 2002-02-11 2003-09-22 Alexion Pharmaceuticals, Inc. Immunotherapeutics for biodefense
US6875433B2 (en) 2002-08-23 2005-04-05 The United States Of America As Represented By The Secretary Of The Army Monoclonal antibodies and complementarity-determining regions binding to Ebola glycoprotein
MXPA05002514A (es) 2002-09-06 2005-05-27 Amgen Inc Anticuerpo monoclonal anti-il-1r1 humano terapeutico.
US7261893B2 (en) 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
AU2003293543A1 (en) 2002-12-13 2004-07-09 Abgenix, Inc. System and method for stabilizing antibodies with histidine
US20050158303A1 (en) 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
EP1471152A1 (en) 2003-04-25 2004-10-27 Institut National De La Sante Et De La Recherche Medicale (Inserm) Mutations in the human PCSK9 gene associated to hypercholesterolemia
EP1633785B1 (en) 2003-05-21 2012-11-28 Medarex, Inc. Human monoclonal antibodies against bacillusanthracis protective antigen
US20050118625A1 (en) 2003-10-02 2005-06-02 Mounts William M. Nucleic acid arrays for detecting gene expression associated with human osteoarthritis and human proteases
JP2005130764A (ja) 2003-10-30 2005-05-26 Pharmaceuticals & Medical Devices Agency Ｎａｒｃ−１遺伝子上の多型を利用した脂質代謝異常に起因する疾患の検査方法、および創薬のための用途
SI2409713T1 (sl) 2004-08-10 2015-10-30 Genzyme Corporation Oligonukleotidi za uporabo pri uravnavanju nivojev lipoproteinov in holesterola pri ljudeh
US20060147945A1 (en) 2005-01-06 2006-07-06 Edmonds Brian T Novel secreted proteins and their uses
WO2006081171A1 (en) 2005-01-24 2006-08-03 Amgen Inc. Humanized anti-amyloid antibody
US7682981B2 (en) * 2005-01-27 2010-03-23 Contour Semiconductor, Inc. Topography transfer method with aspect ratio scaling
WO2006124269A2 (en) 2005-05-16 2006-11-23 Amgen Fremont Inc. Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
JP5231810B2 (ja) 2005-12-28 2013-07-10 中外製薬株式会社 抗体含有安定化製剤
CN101379397A (zh) 2006-01-26 2009-03-04 Hx诊断公司 H5亚型禽流感病毒血凝素蛋白的单克隆抗体或其结合活性片段及其用途
EP2348106B1 (en) 2006-05-08 2014-07-02 Adaerata, Limited Partnership Chimeric proteins, cells comprising same, and assays using same
US7605251B2 (en) 2006-05-11 2009-10-20 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the PCSK9 gene
US7572618B2 (en) * 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
WO2008042383A1 (en) 2006-10-02 2008-04-10 Armstrong World Industries, Inc. Process for preparing high molecular weight polyesters
US20100068194A1 (en) 2006-10-24 2010-03-18 Dong-Ku Kim Composition for in vivo transplantation for treatment of human cervical cancer comprising mononuclear cells derived from umbilical cord blood
WO2008057457A2 (en) * 2006-11-07 2008-05-15 Merck & Co., Inc. Antagonists of pcsk9
CA2667869A1 (en) 2006-11-07 2008-05-15 Merck & Co., Inc. Antagonists of pcsk9
CA2667894A1 (en) 2006-11-07 2008-05-15 Merck & Co., Inc. Antagonists of pcsk9
WO2008133647A2 (en) * 2006-11-07 2008-11-06 Merck & Co., Inc. Antagonists of pcsk9
FR2909092B1 (fr) 2006-11-24 2012-10-19 Pf Medicament Nouveaux anticorps anti-proliferation
US8093222B2 (en) 2006-11-27 2012-01-10 Isis Pharmaceuticals, Inc. Methods for treating hypercholesterolemia
EA200900741A1 (ru) 2006-11-27 2010-04-30 Айзис Фармасьютикалз, Инк. Способы лечения гиперхолестеринемии
JP5086618B2 (ja) * 2006-11-27 2012-11-28 オリンパス株式会社 カプセル型内視鏡
JP5419709B2 (ja) 2007-01-09 2014-02-19 ワイス・エルエルシー 抗ｉｌ−１３抗体製剤およびその使用
WO2008109871A2 (en) 2007-03-08 2008-09-12 Irm Llc Crystal structure of proprotein convertase 9 (pcsk9) and uses thereof
AR066042A1 (es) * 2007-04-13 2009-07-22 Novartis Ag Moleculas y metodos para modular la proteina convertasa-subtilisina /quexina tipo 9 (pcsk9)
CN102083861B (zh) 2007-08-13 2016-04-13 瓦斯基因治疗公司 使用结合EphB4的人源化抗体的癌症治疗
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
US20130072665A1 (en) 2007-08-23 2013-03-21 Simon Mark Jackson Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9)
EP4248976B1 (en) 2007-08-23 2026-04-22 Amgen Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9)
CN102232088A (zh) 2007-10-26 2011-11-02 先灵公司 用于治疗脂类和胆固醇疾病的抗pcsk9及方法
CA2713379A1 (en) 2008-01-31 2009-11-05 Alnylam Pharmaceuticals, Inc. Optimized methods for delivery of dsrna targeting the pcsk9 gene
CN101986784A (zh) 2008-02-07 2011-03-16 先灵公司 基因工程tslpr抗体
AR070315A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Anticuerpos 1b20 antagonistas de pcsk9
AR070316A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
TW201920257A (zh) 2008-04-11 2019-06-01 日商中外製藥股份有限公司 重複結合複數個抗原的抗原結合分子
EP2296694B1 (en) 2008-04-23 2015-08-05 Amgen Inc. Neutralizing proprotein convertase subtilisin kexin type 9 (pcsk9) variants and uses thereof
EP2315779A2 (en) 2008-07-09 2011-05-04 Biogen Idec MA Inc. Compositions comprising antibodies to lingo or fragments thereof
DE102008034203B4 (de) * 2008-07-21 2018-04-26 Airbus Helicopters Deutschland GmbH Herstellung von Faserverbundbauteilen mit Formkernen
EP2641918A3 (en) 2008-08-04 2014-03-05 Amgen Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
TWI445716B (zh) 2008-09-12 2014-07-21 Rinat Neuroscience Corp Ｐｃｓｋ９拮抗劑類
WO2010068526A1 (en) 2008-12-12 2010-06-17 Merck Sharp & Dohme Corp. Pcsk9 immunoassay
US20130064834A1 (en) 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
US8357371B2 (en) 2008-12-15 2013-01-22 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to PCSK9
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
PE20120359A1 (es) 2009-03-06 2012-04-13 Genentech Inc Formulacion con anticuerpo
US8210622B2 (en) 2009-03-13 2012-07-03 Liberty Hardware Mfg. Corp. Adjustable product display assembly
WO2011028938A1 (en) 2009-09-02 2011-03-10 Alnylam Pharmaceuticals, Inc. Methods for lowering serum cholestrol in a subject using inhibition of pcsk9
US20120219558A1 (en) 2009-09-25 2012-08-30 Yan Ni Antagonists of pcsk9
NZ599323A (en) 2009-10-15 2014-06-27 Univ Monash Affinity ligands and methods for protein purification
CA2777698A1 (en) 2009-10-30 2011-05-05 Merck Sharp & Dohme Corp. Ax1 and ax189 pcsk9 antagonists and variants
AU2010313324A1 (en) 2009-10-30 2012-04-12 Merck Sharp & Dohme Corp. AX213 and AX132 PCSK9 antagonists and variants
WO2011053743A1 (en) 2009-10-30 2011-05-05 Merck Sharp & Dohme Corp. Pcsk9 immunoassay
WO2011053665A1 (en) 2009-10-30 2011-05-05 Merck Sharp & Dohme Corp. Pcsk9 immunoassay
PL3721904T3 (pl) 2009-11-20 2022-01-31 Biocon Limited Formulacje przeciwciała t1h
AR079336A1 (es) 2009-12-11 2012-01-18 Irm Llc Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)
NZ602220A (en) 2010-03-11 2014-10-31 Rinat Neuroscience Corp Antibodies with ph dependent antigen binding
DK2558491T3 (en) * 2010-04-13 2018-10-15 Bristol Myers Squibb Co Fibronectin-based Scaffold domain proteins that bind PCSK9
CN201712554U (zh) 2010-07-14 2011-01-19 李辉 电动汽车热管理系统
WO2012054438A1 (en) 2010-10-22 2012-04-26 Schering Corporation Anti-pcsk9
CA2817015A1 (en) 2010-11-09 2012-05-18 Altimab Therapeutics, Inc. Protein complexes for antigen binding and methods of use
US8613308B2 (en) 2010-12-10 2013-12-24 Uop Llc Process for transferring heat or modifying a tube in a heat exchanger
CN103261230A (zh) 2010-12-22 2013-08-21 霍夫曼-拉罗奇有限公司 抗pcsk9抗体及使用方法
EP2650016A1 (en) 2011-01-28 2013-10-16 Sanofi Human antibodies to PSCK9 for use in methods of treatment based on particular dosage regimens (11565)
CA2825778A1 (en) 2011-01-28 2012-08-02 Sanofi Pharmaceutical compositions comprising human antibodies to pcsk9
EP2481758A1 (en) 2011-01-28 2012-08-01 Sanofi Human antibodies to PSCK9 for use in methods of treating particular groups of subjects (11566)
MX2013009258A (es) 2011-02-11 2013-10-17 Novartis Ag Antagonistas de pcsk9.
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
US20140004122A1 (en) * 2011-05-10 2014-01-02 Amgen Inc. Methods for treating or preventing cholesterol related disorders
WO2012168491A1 (en) 2011-06-10 2012-12-13 Novartis Ag Pharmaceutical formulations of pcsk9 antagonists
WO2012170607A2 (en) 2011-06-10 2012-12-13 Novartis Ag Use of pcsk9 antagonists
KR20140041747A (ko) 2011-06-20 2014-04-04 제넨테크, 인크. Pcsk9-결합 폴리펩티드 및 사용 방법
WO2013008185A1 (en) 2011-07-14 2013-01-17 Pfizer Inc. Treatment with anti-pcsk9 antibodies
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
ES2773111T3 (es) 2011-09-16 2020-07-09 Regeneron Pharma Inhibidor de la proproteína convertasa subtilisina/kexina 9 (PCSK9) para su uso en la reducción de los niveles de lipoproteína (a)
AR087715A1 (es) 2011-09-16 2014-04-09 Lilly Co Eli Anticuerpos anti pcsk9 y usos de los mismos
CN104169304A (zh) 2011-12-20 2014-11-26 阿达拉塔合伙有限公司 作为pcsk9抑制剂的单域抗体
WO2013148284A1 (en) 2012-03-29 2013-10-03 Genentech, Inc. Antibodies that bind to a pcsk9 cleavage site and methods of use
EA039663B1 (ru) * 2012-05-03 2022-02-24 Амген Инк. Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
WO2013180295A1 (ja) 2012-06-01 2013-12-05 日本電信電話株式会社 パケット転送処理方法およびパケット転送処理装置
AR091462A1 (es) 2012-06-15 2015-02-04 Genentech Inc Anticuerpos anti-pcsk9, formulaciones, dosificacion y metodos de uso
EP2703009A1 (en) 2012-08-31 2014-03-05 Sanofi Combination treatments involving antibodies to human PCSK9
EP2706070A1 (en) 2012-09-06 2014-03-12 Sanofi Combination treatments involving antibodies to human PCSK9
AU2014235430A1 (en) 2013-03-15 2015-09-24 Amgen Inc. Human antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9 (PCSK9)
JP6071725B2 (ja) 2013-04-23 2017-02-01 カルソニックカンセイ株式会社 電気自動車の駆動力制御装置
US20150004174A1 (en) 2013-06-28 2015-01-01 Amgen Inc. Methods for treating homozygous familial hypercholesterolemia
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof
EP3197492A1 (en) 2014-09-23 2017-08-02 Pfizer Inc Treatment with anti-pcsk9 antibodies
US11284893B2 (en) 2019-04-02 2022-03-29 Covidien Lp Stapling device with articulating tool assembly
DE102023206495B3 (de) 2023-07-07 2024-11-21 Volkswagen Aktiengesellschaft Integrierter Schaltkreis, Anordnung sowie Verfahren zum Einkoppeln von optischen Signalen in einen integrierten Schaltkreis

Also Published As

Publication number Publication date
MX2020008898A (es) 2020-10-12
JP2020058376A (ja) 2020-04-16
US20150031870A1 (en) 2015-01-29
US8030457B2 (en) 2011-10-04
US9056915B2 (en) 2015-06-16
NL300818I2 (enExample) 2016-07-14
JP2015166345A (ja) 2015-09-24
PE20180173A1 (es) 2018-01-22
CY2016023I1 (el) 2017-04-26
HRP20230503T3 (hr) 2023-09-15
US9493576B2 (en) 2016-11-15
US20120020976A1 (en) 2012-01-26
JP2016182114A (ja) 2016-10-20
HRP20160494T1 (hr) 2016-06-03
EP2215124B9 (en) 2023-12-27
SG184702A1 (en) 2012-10-30
PE20140220A1 (es) 2014-02-21
MX2010001921A (es) 2010-03-11
CN104311667A (zh) 2015-01-28
JP5441905B2 (ja) 2014-03-12
US20150087819A1 (en) 2015-03-26
US20120020975A1 (en) 2012-01-26
IL273353B2 (en) 2024-01-01
ES2946083T3 (es) 2023-07-12
DK3666797T5 (da) 2024-08-26
AR068011A1 (es) 2009-10-28
DK2215124T4 (da) 2024-01-29
US8563698B2 (en) 2013-10-22
CN113402611A (zh) 2021-09-17
UA127402C2 (uk) 2023-08-16
PH12013502285B1 (en) 2024-04-12
SI2215124T2 (sl) 2023-11-30
SG10201710183TA (en) 2018-01-30
EP3202791A1 (en) 2017-08-09
US8981064B2 (en) 2015-03-17
CY2016029I1 (el) 2017-04-26
US8829165B2 (en) 2014-09-09
CO6230997A2 (es) 2010-12-20
IL304868A (en) 2023-10-01
KR20200074262A (ko) 2020-06-24
FI2215124T4 (fi) 2023-10-10
PE20140014A1 (es) 2014-01-31
LT3666797T (lt) 2023-08-10
PT3666797T (pt) 2023-06-07
TW201500374A (zh) 2015-01-01
HRP20160494T4 (hr) 2023-10-27
PH12013502286A1 (en) 2016-02-22
JP6638009B2 (ja) 2020-01-29
JP5906333B2 (ja) 2016-04-20
US20140228547A1 (en) 2014-08-14
JP2018118974A (ja) 2018-08-02
CA2696252C (en) 2016-06-14
CN104311665A (zh) 2015-01-28
US20140357850A1 (en) 2014-12-04
BRPI0816117B8 (pt) 2021-05-25
US8889834B2 (en) 2014-11-18
HK1143824A1 (zh) 2011-01-14
JOP20080381B1 (ar) 2023-03-28
US20130052201A1 (en) 2013-02-28
EP3666797A1 (en) 2020-06-17
MA31978B1 (fr) 2011-01-03
NO2016010I1 (no) 2016-06-03
LU93180I2 (fr) 2016-10-18
US20090326202A1 (en) 2009-12-31
CR11328A (es) 2010-07-12
BR122018012430B8 (pt) 2021-07-27
JP2014043446A (ja) 2014-03-13
MY180102A (en) 2020-11-22
US20120027765A1 (en) 2012-02-02
US8871913B2 (en) 2014-10-28
TWI675847B (zh) 2019-11-01
US20120093818A1 (en) 2012-04-19
KR20170012592A (ko) 2017-02-02
US20130245235A1 (en) 2013-09-19
DE202008018562U1 (de) 2015-11-02
CY2016023I2 (el) 2017-04-26
JP2026062754A (ja) 2026-04-10
DK2215124T3 (en) 2016-05-30
TW202330625A (zh) 2023-08-01
US20130085265A1 (en) 2013-04-04
US20140235831A1 (en) 2014-08-21
ES2917423T3 (es) 2022-07-08
US9920134B2 (en) 2018-03-20
DE19207796T1 (de) 2022-03-10
PE20140221A1 (es) 2014-02-21
IL252616A0 (en) 2017-07-31
ES2573258T3 (es) 2016-06-06
US20120251544A1 (en) 2012-10-04
KR20260006647A (ko) 2026-01-13
US20120213797A1 (en) 2012-08-23
PE20221507A1 (es) 2022-10-04
US20140357852A1 (en) 2014-12-04
KR20140064962A (ko) 2014-05-28
LTPA2016025I1 (lt) 2016-09-12
IL273353B1 (en) 2023-09-01
US20140228557A1 (en) 2014-08-14
ES3071736T3 (en) 2026-06-25
US20140235830A1 (en) 2014-08-21
WO2009026558A1 (en) 2009-02-26
KR20210028741A (ko) 2021-03-12
HUE028162T2 (en) 2016-12-28
LTC2215124I2 (lt) 2023-04-25
BR122018012430B1 (pt) 2019-10-08
ES2573258T5 (es) 2024-02-23
MY199051A (en) 2023-10-11
AU2008288791A1 (en) 2009-02-26
DK3666797T3 (da) 2023-05-30
EP2215124B1 (en) 2016-02-24
AU2008288791B2 (en) 2014-10-30
NZ584101A (en) 2012-09-28
PH12013502285A1 (en) 2016-08-08
CN101932607A (zh) 2010-12-29
FR16C0025I2 (fr) 2018-06-08
TW200916481A (en) 2009-04-16
EA032106B1 (ru) 2019-04-30
CN112415203A (zh) 2021-02-26
EP3666797B1 (en) 2023-05-17
TWI441833B (zh) 2014-06-21
US8859741B2 (en) 2014-10-14
CY2016029I2 (el) 2017-04-26
NO2016015I1 (no) 2016-08-12
US20110027287A1 (en) 2011-02-03
CN112390889A (zh) 2021-02-23
HUS1600036I1 (hu) 2016-10-28
IL252616B (en) 2020-05-31
IL204013B2 (en) 2025-07-01
PL2215124T5 (pl) 2023-11-20
US20140228545A1 (en) 2014-08-14
KR20240113594A (ko) 2024-07-22
PE20140231A1 (es) 2014-03-08
KR101494932B1 (ko) 2015-02-26
NO2023012I1 (no) 2023-03-20
RS54756B1 (sr) 2016-10-31
JP5705288B2 (ja) 2015-04-22
US9045547B2 (en) 2015-06-02
IL204013A (en) 2017-07-31
TWI633122B (zh) 2018-08-21
FR16C0025I1 (fr) 2016-07-08
US20090142352A1 (en) 2009-06-04
LU93096I2 (fr) 2016-08-01
HUE062493T2 (hu) 2023-11-28
TWI890005B (zh) 2025-07-11
TWI675848B (zh) 2019-11-01
KR20180035947A (ko) 2018-04-06
LTPA2016021I1 (lt) 2016-06-27
PL2215124T3 (pl) 2016-08-31
KR101702194B1 (ko) 2017-02-03
US8168762B2 (en) 2012-05-01
TN2010000063A1 (en) 2011-09-26
PL3666797T3 (pl) 2023-08-28
PE20131400A1 (es) 2013-12-16
BRPI0816117A2 (pt) 2015-03-10
US8883983B2 (en) 2014-11-11
RS64295B1 (sr) 2023-07-31
EP2215124A1 (en) 2010-08-11
TWI799416B (zh) 2023-04-21
TWI675846B (zh) 2019-11-01
PE20091006A1 (es) 2009-08-14
SI3666797T1 (sl) 2023-10-30
TW201716444A (zh) 2017-05-16
US20140357853A1 (en) 2014-12-04
TW201906871A (zh) 2019-02-16
SI2215124T1 (sl) 2016-09-30
RS54756B2 (sr) 2024-07-31
EA201000356A1 (ru) 2010-08-30
CN104311666A (zh) 2015-01-28
KR20220031734A (ko) 2022-03-11
JP2010536384A (ja) 2010-12-02
JP2023071833A (ja) 2023-05-23
CA2696252A1 (en) 2009-02-26
CL2008002495A1 (es) 2009-09-04
IL273353A (en) 2020-05-31
DE19207796T9 (de) 2023-02-23
BRPI0816117B1 (pt) 2018-12-18
TW201500376A (zh) 2015-01-01
US8871914B2 (en) 2014-10-28
KR20230080496A (ko) 2023-06-07
US20130058944A1 (en) 2013-03-07
US20140357851A1 (en) 2014-12-04
CN101932607B (zh) 2014-06-25
HUS1600029I1 (hu) 2016-09-28
US20130079501A1 (en) 2013-03-28
US20130079502A1 (en) 2013-03-28
CN112409489A (zh) 2021-02-26
MX375117B (es) 2025-03-06
EP2215124B2 (en) 2023-07-19
MY199053A (en) 2023-10-11
CY1117940T1 (el) 2017-04-26
KR20100057070A (ko) 2010-05-28
TW201500375A (zh) 2015-01-01
US20140357854A1 (en) 2014-12-04
IL317213A (en) 2025-01-01

Similar Documents

Publication Publication Date Title
HRP20230503T3 (hr) Proteini koji vežu antigen na proprotein konvertaza subtilizin/keksin tip 9 (pcsk9)
JP2011500843A5 (enExample)
Delbaldo et al. Phase I and pharmacokinetic study of etaracizumab (Abegrin™), a humanized monoclonal antibody against αvβ3 integrin receptor, in patients with advanced solid tumors
JP2019514907A5 (enExample)
JP2017528427A5 (enExample)
Waters et al. Effects of high-dose atorvastatin on cerebrovascular events in patients with stable coronary disease in the TNT (treating to new targets) study
HRP20200545T1 (hr) Postupci liječenja ili sprječavanja poremećaja povezanih sa kolesterolom
JP2022133396A5 (enExample)
HRP20241450T1 (hr) Postupci za smanjivanje razina lipoproteina(a) putem primjene inhibitora proproteinske konvertaze suptilizin keksin 9 (pcsk9)
JP2011519277A5 (enExample)
RU2012150953A (ru) Моноклональные антитела против активированного протеина с
RU2013139727A (ru) Антитела человека к pcsk9 для применения в способах лечения конкретных групп индивидуумов
HRP20170488T1 (hr) Humana antitijela s visokim afinitetom prema pcsk9
JP2014516953A5 (enExample)
MA31899B1 (fr) Anticorps monoclonaux qui se lient au hgm-csf et compositions medicales les comprenant
WO2010054265A3 (en) Monoclonal antibodies to fibroblast growth factor receptor 2
WO2005102387A3 (en) Therapeutic use of anti-cs1 antibodies
CY1106879T1 (el) Χρηση των αναστολεων αναγωγασης συνενζυμου α 3-υδροξυ-3-μεθυλογλουταρυλ για την παρασκευη ενος φαρμακου για την αντιμετωπιση της διαβητικης νευροπαθειας
JP2010512320A5 (enExample)
WO2005054294A3 (en) Inhibitors of glycoprotein vi based on monoclonal antibody hgp 5c4
JP2019533715A (ja) アテローム動脈硬化性心血管疾患を含むアテローム性動脈硬化症の併用療法
Aradine et al. Current status of dyslipidemia treatment for stroke prevention
Sirenko et al. Impact of statin therapy on the blood pressure-lowering efficacy of a single-pill perindopril/amlodipine combination in hypertensive patients with hypercholesterolemia
Undas et al. Atorvastatin and quinapril inhibit blood coagulation in patients with coronary artery disease following 28 days of therapy
Erb Single-enantiomer drugs poised for further market growth